Cordis Stresses Durability Of Fortron AAA System, European Safety Results
This article was originally published in The Gray Sheet
The positive safety profile of Johnson & Johnson/ Cordis' Fortron abdominal aortic aneurysm (AAA) stent graft, as demonstrated in Europe, likely will be a key component of the firm's U.S. marketing strategy
You may also be interested in...
Guidant is poised to exit the abdominal aortic aneurysm market, which could eventually reach $1 bil., citing declining sales and a lack of adoption by vascular surgeons of its Ancure AAA endovascular stent graft
The UK Medical Devices Agency expects Medtronic to make available a re-designed version of the Talent abdominal aortic aneurysm (AAA) stent graft soon, following reported post-implantation device fractures in U.S. premarket clinical trials
Johnson & Johnson/Cordis will join a crowded field of players in the worldwide abdominal aortic aneurysm (AAA) market, expected to top $1 bil. by 2008, following the acquisition of privately-held Teramed